Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Monopar Therapeutics Inc (MNPR) has issued an announcement.
Monopar Therapeutics Inc. has announced the milestone achievement of successfully administering their uPAR-targeted imaging radiopharmaceutical, MNPR-101-Zr, to the first patient in an open-label Phase 1 clinical trial. This marks a significant step forward in their efforts to advance this innovative diagnostic tool in the medical field.
For a thorough assessment of MNPR stock, go to TipRanks’ Stock Analysis page.
